> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly's Oral GLP-1 Outperforms Oral Semaglutide in Diabetes Trial
- URL: https://www.fdaweb.com/lillys-oral-glp-1-outperforms-oral-semaglutide-in-diabetes-trial/
- Published: 2026-06-09T12:00:00.000Z
- Updated: 2026-09-14T13:40:47.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161281

Eli Lilly is reporting detailed Phase 3 results Monday showing its oral GLP-1 receptor agonist Foundayo (orforglipron) outperformed Novo Nordisk's oral semaglutide on blood sugar control and weight loss in what the company described as the first head-to-head late-stage trial comparing two oral GLP-1 therapies for Type 2 diabetes.

The findings, presented at the American Diabetes Association Scientific Sessions, come as Lilly prepares to submit Foundayo to FDA for a Type 2 diabetes indication by the end of the month under the agency's National Priority Review Voucher program.

[Lilly says](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-foundayo-orforglipron-delivered-superior-a1c?ref=fdaweb.com) the Phase 3 ACHIEVE-3 study, which enrolled 1,698 adults with Type 2 diabetes inadequately controlled on metformin. At 52 weeks, patients receiving Foundayo's highest dose of 17.2 mg achieved a 2.2 percentage-point reduction in A1C compared with a 1.4 percentage-point reduction for oral semaglutide 14 mg. Lilly said the result represented a 57.1% greater relative reduction in A1C.

Weight-loss results also favored Foundayo. Patients receiving the 17.2 mg dose lost an average 19.7 pounds, or 9.2% of body weight, compared with 11 pounds, or 5.3% of body weight, among those receiving oral semaglutide 14 mg. Lilly calculated the difference as a 73.6% greater relative weight reduction.

Lilly also released detailed results from two additional Phase 3 studies.

The data strengthen Lilly's effort to establish Foundayo as a leading oral incretin therapy in a market currently dominated by injectable GLP-1 agents and Novo Nordisk's oral semaglutide product, Rybelsus.